Jain Global’s AbCellera Biologics ABCL Stock Holding History

Jain Global’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-54,918	Closed	-$122K	–	1136
2025 Q1	$122K	Buy	+54,918	New	+$158K	﹤0.01%	943

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jain Global's ABCL Position: Q2 2025 in Review

Jain Global sold out of AbCellera Biologics (ABCL) in Q2 2025, closing a stake of 54,918 shares — an estimated $122K sold.

Jain Global first reported a position in ABCL in Q1 2025 and held it in 1 quarter. The position peaked at $122K in Q1 2025. 128 funds tracked by Wall St. Rank hold ABCL as of Q2 2025.

Jain Global reported no remaining AbCellera Biologics position as of Q2 2025 after selling out during the quarter.
Jain Global sold 54,918 AbCellera Biologics shares in Q2 2025, an estimated $122K.
Jain Global first reported a position in AbCellera Biologics in Q1 2025 and held it in 1 quarter.
Jain Global's AbCellera Biologics position peaked at $122K in Q1 2025.
128 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2025.

Based on Jain Global's 13F filing for Q2 2025, filed 14 Aug 2025.